Cargando…
Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Human epidermal growth factor receptor 2–positive (HER2(+)) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2(+) breast cancer. In this narrative review, we summarize advances...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067811/ https://www.ncbi.nlm.nih.gov/pubmed/32195333 http://dx.doi.org/10.1038/s41523-020-0153-3 |